RANGERS SIGN FROLOV The Rangers added some offensive punch by agreeing to terms with the longtime Los Angeles Kings forward Alexander Frolov, who they hope will be a potent complement to Marian Gaborik on the Rangers' top line.
Recent studies have demonstrated that this enzyme is inhibited by compstatin (Morikis, D., Assa-Munt, N., Sahu, A., Lambris, J.D., 1998. Solution structure of Compstatin, a potent complement inhibitor. Protein Sci. (7) 619 627; Sahu, A., Kay, B.K., Lambris, J.D., 1996.
Teleosts do possess a potent complement system [56], [57], a functional C5a homologue [58], [59], and a corresponding receptor [60], [61], so it is plausible that a fish pathogen would target components of this pathway.
Unlike IgG, IgM is a potent complement activator but, as previously mentioned, is usually not found on the RBC surface by DAT in w-AIHA [ 19].
Rather, the attention has been turned to a potent complement inhibitor, C1-INH, widely used in the treatment of hereditary angioedema.
Investigating different citrate concentrations clearly showed that citrate is a potent complement inhibitor already at low concentrations, i.e. 0.25 mM, which is comparable with concentrations detected in the blood of patients during dialysis with citrate-containing fluids.
The use of GT-KO pigs (in association with the human CD46 transgenes) as pig islet donors did not show a substantial protective effect toward early islet loss, suggesting that perhaps antibody binding to non-Gal antigens would likely be a more potent complement activator [ 16, 17, 23].
The human pathogen Staphylococcus aureus has evolved a sophisticated and potent complement evasion strategy, which is predicated upon an arsenal of potent inhibitory proteins.
Zymosan (particles from the cell wall of Saccharomyces cerevisiae) is a standard and potent complement activator but it is not safe for clinical use (Volman et al, 2002), while streptokinase and urokinase are clinically acceptable but are primarily acting as anticoagulating agents (Ewald and Eisenberg, 1995; Oren et al, 1998).
Although in a direct comparison with the potent complement activator zymosan, using B16BL6 melanoma model, γ-inulin has not statistically proven significantly more effective in delaying the recurrence of PDT-treated tumours, it produced on average over three-fold increase in tumour recurrence time (compared to PDT only group) while this increase with zymosan was only two-fold.
Our results indicate that the CR1-based protein may be a model for developing smaller and more potent complement inhibitors for future therapeutics.
